Insulin aspart
- Generic Name
- Insulin aspart
- Brand Names
- Fiasp, Novolog, Novolog Mix, Novomix, Novorapid, Novorapid Penfill, Ryzodeg, Truvelog Mix 30, Kirsty (previously Kixelle), NovoRapid, Insulin aspart Sanofi, NovoMix
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 116094-23-6
- Unique Ingredient Identifier
- D933668QVX
- Background
Insulin aspart is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin ...
- Indication
Insulin aspart is indicated to improve glycemic control in adults and children with diabetes mellitus.
- Associated Conditions
- Diabetes Mellitus, Diabetic Ketoacidosis, Gestational Diabetes Mellitus (GDM), Hyperglycemia during critical illness
- Associated Therapies
- -
Using the Inflation Reduction Act to Rein in Patenting & Evergreening Abuses
The Inflation Reduction Act allows CMS to negotiate Medicare drug prices, exposing patent abuses like evergreening. Four of 10 drugs would have faced competition, saving Medicare $4.9-$5.4B. Nine drugs show evidence of anticompetitive patent practices, delaying affordable alternatives. CMS must consider these practices to ensure fair prices for Medicare beneficiaries.
Drug Prices Negotiated by Medicare Still Higher Than Other Countries'
Negotiated prices for 10 Medicare drugs fell from initial net prices, with reductions ranging from 8% to 42%, but all except insulin aspart remained more expensive in the U.S. than in peer countries. The study highlights the need for continued assessment of future negotiation rounds, especially with potential inclusion of Part B drugs, to maximize savings.
Novo Nordisk CEO Agrees to Work With PBMs to Negotiate Lower Semaglutide List Prices
Novo Nordisk CEO Lars Fruergaard Jørgensen agrees to negotiate lower list prices for Ozempic and Wegovy with US Senate HELP Committee and PBMs, following written commitments from 'Big 3' PBMs to expand coverage if prices are reduced. US prices for these drugs are significantly higher than in Europe, leading to limited access for many Americans.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath